Stable coronary heart disease complicated with anxiety and depression
Conditions
Interventions
Test group:Oral administration of Xuefu Zhuyu Tang granules.
control group:Oral administration of Xuefu Zhuyu Tang granules placebo.
Sponsors
Shandong University of Traditional Chinese Medicine Affiliated Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Patients who meet the Western diagnostic criteria for stable coronary heart disease and are accompanied by anxiety and depression; 2. Meet the diagnostic criteria of traditional Chinese medicine for chest obstruction heartache qi stagnation and blood stasis syndrome; 3. Individuals with a HAMA score of 7-28 and/or a HAMD score of 8-35 are classified as having mild to moderate anxiety and depression; 4. Have not used other anti anxiety and depression medications in the past 4 weeks; 5. Age range of 18-80 years old (including 18 and 80 years old) regardless of gender; 6. The subjects voluntarily participate in this experimental study have good compliance and can be followed up for a long time and sign an informed consent form.
Exclusion criteria
Exclusion criteria: 1. Patients with acute myocardial infarction unstable angina and angina severity grade IV; 2. Patients with ST-T changes on electrocardiogram due to digitalis drugs myocardial hypertrophy left bundle branch block and other reasons; 3. Patients who expect or plan to undergo coronary artery cerebrovascular or peripheral artery revascularization surgery or other major surgical procedures during the clinical research process; 4. Coronary angiography shows severe vascular disease: left main artery diameter stenosis>50%; The diameter stenosis of the proximal segment of the anterior descending branch is greater than 70%; Disease vessel diameter stenosis = 90%; When the diameter of the diseased vessel is narrowed by less than 90% the fractional flow reserve is = 0.8; 5. Patients with concurrent organ damage or disease: those with severe cerebrovascular disease (cerebral hemorrhage subarachnoid hemorrhage extensive cerebral infarction); Poor control of diabetes (fasting blood glucose>11 mmol/L) or patients with kidney disease and peripheral neuropathy; Decompensated heart failure (NYHA class III-IV) recurrent malignant arrhythmias poorly controlled hypertension (controlled systolic blood pressure = 180 mmHg or diastolic blood pressure = 100 mmHg); Individuals who have used pacemakers and have a history of cerebrovascular disease within one year; People with respiratory failure chronic lung disease accompanied by breathing difficulties; Individuals with renal insufficiency (creatinine greater than the upper limit of normal glomerular filtration rate (eGFR)<30 ml · min-1 · (1.73 m ²) -1); Abnormal liver function (ALT AST greater than 3 times the upper limit of normal); Gastrointestinal lesions or gastrointestinal surgery may affect drug absorption and other serious digestive system diseases; Those who have combined malignant tumors hematological diseases or other serious or progressive systemic diseases. Combining other diseases and being deemed unsuitable for inclusion by researchers; 6. Patients who have participated in clinical trials of other drugs within the past 3 months prior to enrollment; 7. Pregnant or lactating women or those who have recently planned a pregnancy; 8. Patients with other mental illnesses consciousness disorders cognitive impairments or other reasons who are unable or unwilling to cooperate; 9. Suspect or have a history of alcohol or drug abuse; 10. Individuals with allergies or allergies to drug ingredients; 11. Researchers believe that other patients who are not suitable to participate in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hamilton Anxiety Scale;Hamilton Depression Scale;Traditional Chinese Medicine Syndrome Points;Seattle Angina Questionnaire Score; | — |
Secondary
| Measure | Time frame |
|---|---|
| low density lipoprotein;echocardiography;Fasting blood glucose;total cholesterol;high density lipoprotein;Angina attack situation;triglyceride;electrocardiogram;Clinical outcome evaluation scale scores reported by patients with coronary heart disease and angina pectoris; | — |
Countries
China
Contacts
Public ContactWang Zhenyuan
Shandong University of Traditional Chinese Medicine Affiliated Hospital
Outcome results
None listed